Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 24, 2021-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news